• In August 2026, Surgery Partners, Inc. reported second-quarter 2026 results showing sales of US$848.9 million versus US$826.2 million a year earlier, alongside a higher net loss of US$15.0 million, while also disclosing no share repurchases under its March 2026 buyback authorization to date.
• Management highlighted that disciplined M&A and portfolio optimization have led to only an immaterial level of acquisitions so far in 2026, and that total M&A spending will fall short of its US$200.0 million annual investment target despite an active pipeline and continued focus on short-stay surgical assets.
• We will now examine how this combination of revenue growth, wider losses, and more selective M&A activity influences Surgery Partners’ investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

Surgery Partners Investment Narrative Recap

To own Surgery Partners, you need to believe that outpatient surgery volumes and case mix can eventually translate growing revenue into consistent profits, despite ongoing losses and a leveraged balance sheet. The latest results show modest top-line growth but a wider net loss, while M&A spend is tracking below the US$200.0 million target. This mainly reinforces, rather than changes, the key near term catalyst of execution on higher acuity growth, and the biggest risk from slower than planned acquisition-driven expansion.

The most relevant recent announcement is management’s August 2026 update that M&A activity has been “immaterial” year to date and will not reach the US$200.0 million annual target. Given how central disciplined acquisitions and portfolio optimization are to the growth story, this shortfall heightens the existing risk that a slower deal pace could weigh on incremental EBITDA and make it harder to hit revenue and earnings goals tied to acquisition timing.

Yet beneath this focus on discipline, investors should be aware that rising interest costs and slower deployment of M&A capital could together...

Surgery Partners' narrative projects $4.0 billion revenue and $72.9 million earnings by 2029. This requires 5.9% yearly revenue growth and about a $149 million earnings increase from -$76.1 million today.

Uncover how Surgery Partners' forecasts yield a $17.95 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts saw revenue reaching about US$4.1 billion and earnings near US$148 million by 2029, but with Q2 losses widening and higher interest costs in focus, you can see how their much rosier margin and growth assumptions might be challenged and why it is useful to compare several very different viewpoints before deciding what you think is realistic.

Explore 3 other fair value estimates on Surgery Partners - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Surgery Partners research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Surgery Partners research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Surgery Partners' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.